EGF in Skincare: How Epidermal Growth Factor Works

Medically Reviewed by Dr. Lisa Hartford, MD

Published April 30, 2026 · Last reviewed April 30, 2026 · Written by the EvenSkyn Skin Science Desk · 4,900 words · 19-minute read

Key takeaways

EGF is a 53-amino-acid polypeptide that signals skin cells to divide, migrate, and repair. Stanley Cohen isolated it in the early 1960s and won the 1986 Nobel Prize in Physiology or Medicine for the discovery.
Topical EGF has a delivery problem. At roughly 6 kDa molecular weight, the molecule sits well above the practical permeability ceiling of intact skin (about 500 daltons). Most of what you put on your face never reaches the cells it is meant to signal.
Microinfusion bypasses that barrier. Temporary micro-channels through the stratum corneum let EGF reach the upper papillary dermis where its receptors live, in concentrations a topical cream cannot match.
Real clinical results take 8 to 12 weeks of consistent bi-weekly sessions. Anyone promising overnight results is selling hydration, not signaling.
EGF is mitogenic, not mutagenic. It does not cause skin cancer. The persistent internet rumor saying otherwise traces to a CSIRO sheep-shearing technology that has nothing to do with topical or microinfused human use.
Concentration is more important than brand. Look for serums listing rh-Oligopeptide-1 at 10 ppm minimum, ideally 50 ppm or higher for microinfusion delivery.
Do not combine EGF with vitamin C or copper peptides in the same session. They oxidize each other. Rotate across sessions, or use them in separate routine slots.
Real contraindications exist. Active or recent skin cancer, active psoriasis flares on the treatment area, isotretinoin use, and pregnancy are genuine reasons to skip EGF. We list every one of them below.

Why this article exists

Most of what you find online about EGF in skincare falls into two camps. The first is product copy from brands selling EGF serums, which always concludes that EGF is the most important molecule in skincare. The second is contrarian content from a small number of vocal websites arguing EGF is unsafe, repeating a thirty-year-old claim about Australian sheep that has been distorted beyond recognition.

Neither version is honest. The first oversells. The second overclaims risks. Both ignore the most important context for anyone using EGF at home in 2026, which is that the delivery method changes everything. EGF applied as a topical cream is a very different product from EGF infused through micro-channels into the upper dermis. The first is mostly window dressing. The second is genuinely effective.

This article is the second in our microinfusion ingredient series. The first was our complete pillar guide to at-home microinfusion (start there for the broader category context). This piece focuses entirely on EGF: what the peer-reviewed evidence actually says, how to use it intelligently, and what the controversy is really about.

Part 1: What EGF actually is

EGF stands for epidermal growth factor. It is a small polypeptide, 53 amino acids long, that occurs naturally in human tissue and acts as a signaling molecule. Its job is to bind to a receptor on cell surfaces (the EGFR, or epidermal growth factor receptor) and instruct the cell to do specific things: divide, migrate toward a wound, ramp up protein synthesis, repair damage.

The molecule was first isolated in the early 1960s by biochemist Stanley Cohen, who purified it from the submaxillary gland of mice during research on nerve growth. Cohen shared the 1986 Nobel Prize in Physiology or Medicine with Rita Levi-Montalcini, who had discovered the related nerve growth factor.

That history matters because it tells you something the marketing copy does not. EGF was not invented for skincare. It was characterized as a fundamental biological signaling molecule, and used clinically for decades in burn recovery, diabetic ulcer treatment, post-surgical wound healing, and radiation dermatitis management before anyone tried to put it in a face cream. The clinical literature on EGF is enormous, well-established, and largely independent of cosmetic marketing.

In skincare, EGF appears on ingredient panels under one of these names:

rh-Oligopeptide-1. Recombinant human EGF, bioengineered (typically in barley or yeast) to be molecularly identical to human EGF. The most common form in serious products.
sh-Oligopeptide-1. Synthetic human EGF, produced by chemical synthesis rather than recombinant fermentation. Same molecular structure, different manufacturing route.
Epidermal Growth Factor. The plain-English label, often used alongside the INCI name.

If a product says "EGF" or "growth factor" without one of those INCI listings, you cannot verify what is actually in it. Treat it as marketing language until proven otherwise.

Part 2: What the peer-reviewed evidence actually says

The clinical literature on rhEGF is substantial. A 2022 narrative review by Shin and colleagues at Chung-Ang University College of Medicine, published in the International Wound Journal (PMID 36584669, doi 10.1111/iwj.14075), provides one of the most current syntheses of the evidence base. We have used their review for the broader landscape, and have separately verified the specific clinical claims cited below by reading the primary papers directly.

What is well-established

Wound healing and post-procedure recovery. This is the strongest evidence base. rhEGF accelerates re-epithelialization after burns, surgical wounds, and aesthetic procedures including laser resurfacing, chemical peels, and microneedling. Multiple clinical trials, including a phase 3 trial conducted in Korea, have demonstrated significantly reduced healing time for diabetic foot ulcers with topical rhEGF.

Radiation dermatitis. A multicenter prospective cohort study by Kang and colleagues (Kang HC, Ahn SD, Choi DH, Kang MK, Chung WK, Wu HG. Radiation Oncology Journal. 2014;32(3):156-162) enrolled 1,172 cancer patients receiving more than 50 Gy of radiotherapy. Patients treated prophylactically with EGF-based cream showed grade-0 or grade-1 dermatitis rates of 19% and 58% at 50 Gy, rising to 29% and 47% by completion of planned radiotherapy. Adverse events from the EGF cream affected 4% of patients (49 patients), most commonly mild erythema. A separate single-blind randomized preliminary study by Kong et al. in 20 breast cancer patients found that rhEGF-based cream reduced radiation dermatitis severity compared with supportive skin care alone.

Photoaging. The most-cited cosmetic trial is Schouest, Luu and Moy (Schouest JM, Luu TK, Moy RL. Journal of Drugs in Dermatology. 2012;11(5):613-620; PMID 22527430). This was an open-label, single-center study (no placebo control) in 29 women aged 39 to 75, who applied a barley-bioengineered human-like EGF serum twice daily for three months. The investigators reported statistically significant improvement in fine lines and rhytids, skin texture, pore size, and dyschromatic conditions, with effects apparent within the first month and continuing through the study. The study was funded by ORF Genetics, which manufactures the BIOEFFECT serum tested. We note that disclosure here because the trial design was open-label rather than randomized double-blind, which is a meaningful methodological limitation.

Acne and acne scarring. A split-face study by Kim and colleagues evaluated EGF-containing cream in 20 Korean patients with mild-to-moderate acne over six weeks. The treated side showed significant reductions in inflammatory and non-inflammatory lesions, sebum output, and overall acne severity compared with the vehicle-treated side. A separate split-face study of 36 patients later demonstrated reductions in both acne lesion count and acne scarring, with rhEGF appearing to upregulate TGF-β1, elastin, and type 1 and 3 collagen while downregulating pro-inflammatory cytokines.

EGFR-inhibitor-related skin toxicity. Patients receiving anti-cancer EGFR inhibitors often develop acneiform eruptions and xerosis. A pilot phase 3 trial showed rhEGF ointment significantly improved skin lesions and quality-of-life scores compared with placebo in this population.

What the evidence shows about delivery

Here is the part most consumer EGF content skips. The Shin et al. review explicitly states that delivering rhEGF transdermally poses a significant clinical challenge because of its short half-life, large molecular weight, and lack of efficient formulation. This is exactly why drug delivery systems including polymeric nanoparticles, biomedical scaffolds, dissolving microspicules, and microinfusion devices have been the focus of recent dermatology research.

Translation: the studies showing the best results are not the ones using a regular cream. They are the ones using some form of barrier bypass.

This is the entire case for pairing EGF with microinfusion. You are not relying on a 6 kDa protein to magically cross 15 to 20 layers of compressed, lipid-sealed keratinocytes. You are delivering it through micro-channels directly to the cells that have the receptors.

What is still uncertain

The cosmetic-application evidence base has limitations, and an honest article should name them. Most cosmetic studies are small (15 to 50 participants). Many are sponsored by EGF-product manufacturers, which is a known source of bias. Several of the most-cited trials, including the Schouest 2012 paper above, are open-label rather than randomized double-blind. The longest-running studies are typically six to twelve months. Effects beyond that are extrapolated rather than measured. None of this invalidates the use of EGF, but it does mean that any claim like "guaranteed to reverse aging in 30 days" should be ignored on sight.

Part 3: Why EGF and microinfusion are a near-perfect pairing

Three properties of EGF make it specifically well-suited to channel-based delivery.

It is too big to cross intact skin efficiently. At roughly 6 kDa molecular weight, EGF sits well above the practical threshold for unassisted transepidermal absorption, which sits closer to 500 daltons. Some EGF reaches the living skin layers when applied topically, but the fraction is low and variable. Microinfusion lets you deliver a known dose to a known depth.

It is catalytic, not stoichiometric. EGF works by signaling, not by being consumed. A single molecule binds to a receptor, triggers a cascade of downstream effects, and is then internalized and recycled. Even small effective doses can produce meaningful results, as long as they actually reach the cells with receptors. The dose efficiency of microinfusion delivery is unusually well-suited to a catalytic active.

It has a short on-skin half-life. Topical EGF degrades on the surface within hours, partly from oxidation and partly from skin proteases. Sealed delivery into the dermis through fresh micro-channels bypasses both forms of degradation, getting the molecule to its receptors before degradation matters.

The practical consequence: an EGF-loaded microinfusion session at the right concentration delivers more functional EGF to fibroblasts and keratinocytes in five minutes than a daily topical cream delivers in a month. This is why the better at-home microinfusion brands (Qure being the most visible) put EGF in their flagship serums.

Part 4: Reading an EGF serum label honestly

Five things to look for, in order of importance.

1. The INCI name

If the ingredient list shows rh-Oligopeptide-1 or sh-Oligopeptide-1, the product contains real EGF. If it just says "growth factor complex" or "EGF" without an INCI listing, it could be anything from real recombinant EGF to a peptide blend that mimics EGF activity to nothing of consequence at all.

2. The concentration

Concentrations are typically expressed in ppm (parts per million). A reasonable threshold guide:

Under 5 ppm. Marketing labeling. Not enough to do clinically meaningful work.
5 to 10 ppm. Lower end of the range that might produce visible effects with consistent topical use over months.
10 to 50 ppm. Standard range for serious topical EGF serums.
50 to 100 ppm. The range where most clinical effects from consistent topical application become evidenced in published trials.
Over 100 ppm. Premium tier, sometimes used in microinfusion-specific serums where channel delivery means lower total concentration is sufficient.

For microinfusion specifically, anything over 25 ppm is functional. Higher concentrations do not necessarily produce proportionally larger effects because EGF is dose-saturable: above a certain point, you are saturating receptors and additional molecules go to waste.

3. The delivery vehicle

Liposomal or phospholipid-encapsulated EGF protects the protein from degradation and helps it reach target depths. Look for "liposomal," "phospholipid," or "encapsulated" on the formulation description. For microinfusion serums, this matters less because the channels deliver the molecule directly, but it does not hurt.

4. The supporting cast

Smart EGF formulations include molecules that work alongside it without interfering. Good companions:

Niacinamide. Supports barrier repair and reduces inflammation, complementary to EGF's role.
Low-molecular-weight hyaluronic acid. Provides hydration and a stable medium for protein-based actives.
Panthenol. Calms post-treatment skin and supports barrier function.
Adenosine. Anti-inflammatory and synergistic with growth factor signaling.

Bad companions in the same formula:

Vitamin C (L-ascorbic acid, ethyl ascorbic acid). Oxidizes EGF.
Strong acids (glycolic, lactic, salicylic above functional levels). pH incompatibility.
Copper ions or copper peptides. Direct interaction; oxidizes EGF and reduces both ingredients' effectiveness.
Retinoids. Not catastrophic, but pH and oxidation considerations make co-formulation difficult.

5. Packaging

EGF is unstable in air, heat, and light. Look for:

Single-use ampoules (best, especially for microinfusion)
Airless pump bottles with opaque packaging (acceptable for daily topical)
Refrigerated storage instructions (a positive signal that the formulator takes stability seriously)
Manufacturing dates and shelf-life specifications

A multi-use bottle of EGF stored on a bathroom shelf for six months has lost most of its activity by the third month, regardless of preservatives. This is one of the practical reasons single-use ampoules are the gold standard for microinfusion delivery.

Part 5: How to actually use EGF in microinfusion

A real protocol. It aligns with the broader microinfusion protocol from our pillar guide, with EGF-specific adjustments.

Frequency

Every 14 days, same as the standard microinfusion cadence. EGF does not change the cycle. The skin's renewal timeline is what governs frequency, not the active you are using.

Rotation strategy

If you are using multiple ingredient categories (EGF, copper peptides, PDRN), rotate across sessions rather than combining in the same chamber:

Session 1 (week 0): EGF
Session 2 (week 2): Copper peptide (GHK-Cu)
Session 3 (week 4): PDRN
Session 4 (week 6): Back to EGF

Across six weeks, you have delivered all three pathways without formulation conflicts. This is the protocol most aesthetic dermatologists running custom microinfusion practices use, and it is what we recommend for at-home users running multi-ingredient stacks.

Pre-session

48 hours before:

Stop retinoids
Stop vitamin C (oxidation risk)
Stop strong acids
Avoid sun exposure that triggers redness or barrier compromise

Day of session:

Cleanse with a gentle, non-foaming, pH-balanced cleanser
Pat completely dry
Mist with medical-grade hypochlorous acid (Tower 28 SOS Daily Rescue, Clinisept+, and Briotech are all reasonable options)
Allow to air dry

During session

Use a fresh, sterile, single-use stamp head
Pour one ampoule of EGF serum into the chamber
Stamp (do not drag) in 4 to 6 stamps per zone
Work centrally outward: forehead, cheeks, nose, chin
Skip the orbital bone unless your device is specifically approved for the eye area
For under-eye treatment, use dissolving microneedle patches loaded with peptides and hyaluronic acid rather than a stamp

Post-session

First 30 minutes:

Press in any remaining serum from the chamber with clean fingers
No moisturizer, sunscreen, or makeup
Let the channels close

Next 24 hours:

Gentle moisturizer in the morning
Mineral SPF 50+ (zinc oxide preferred for freshly treated skin)
No retinoids, acids, or vitamin C
No sauna, hot yoga, or very hot showers

Next 72 hours:

Continue gentle skincare only
Resume retinoids and vitamin C at hour 72
The compounding effect over multiple sessions becomes visible in weeks 4 to 8

Stack compatibility

EGF microinfusion stacks well with several non-treatment-day adjuncts:

Red light therapy (LED masks). Use 24 hours after a session to amplify barrier recovery and support fibroblast activity. Ideal pairing.
Microcurrent. Same-day microcurrent after microinfusion is generally fine. Different mechanism, different layer.
Radiofrequency (RF) skin tightening. Excellent stack but separate by 48 hours. Do not combine in the same session.
Sunscreen. Non-negotiable. A microinfusion routine without daily SPF is a routine working against itself.

Part 6: Addressing the EGF controversy honestly

A vocal corner of the internet, anchored by Dr. Loren Pickart (the discoverer of GHK-Cu copper peptides) and his commercial site reverseskinaging.com, argues that EGF is unsafe in skincare. The case rests on three claims. We are going to address each directly because pretending the conversation does not exist would be intellectually dishonest, and because addressing it properly is exactly the kind of content that earns the trust of skeptical readers.

Claim 1: "EGF causes hair loss."

The basis is Bioclip, a biological wool-harvesting technology developed by Australia's CSIRO research agency over two decades and commercialized in 1998. The mechanism: a single injection of EGF causes a temporary break in the wool fiber at the follicle level, allowing the entire fleece to be shed within roughly a week and harvested manually. The original mechanism research is documented in Moore GP, Panaretto BA, Carter NB. Journal of Investigative Dermatology. 1985;84(3):172-175 (PMID 3871824), where infusions of 0.17 to 0.72 mg EGF per kg of metabolic body weight over 28 hours caused marked declines in wool follicle bulb cell mitotic indices, with subsequent fleece break.

Why this is irrelevant to topical or microinfused human use:

Dose scale. The CSIRO sheep studies used systemic infusions delivering hundreds of micrograms per kilogram of body weight. Topical or microinfused EGF in skincare delivers nanogram-to-microgram quantities to a localized area of skin, with no systemic effect.
Follicle biology. Sheep wool follicles cycle on a different mechanism than human anagen scalp follicles, and are unusually sensitive to EGF-induced disruption of bulb cell mitosis. EGFR signaling is involved in normal hair cycle progression, but the systemic EGF-causes-shedding effect specific to wool follicles does not transfer to human topical or microinfused dosing.
Adverse event reporting. Published clinical trials of topical or microinfused EGF in humans, including those reviewed in the Shin et al. 2022 paper, do not report hair loss as a recurring adverse event.

Claim 2: "EGF is mutagenic and could cause cancer."

EGF is mitogenic, meaning it promotes cell division. Mitogenic is not the same as mutagenic, which means causing DNA mutations. EGF does not damage DNA. It signals existing cells to divide, just as countless natural growth factors in your body do every day.

The legitimate concern, which is documented in dermatology literature, is that any agent that promotes cell proliferation could theoretically accelerate the growth of a pre-existing malignancy. This is why EGF is not recommended for application over actively growing tumors, areas with a recent history of skin cancer, or in patients with active malignancy elsewhere.

Importantly, the Shin et al. 2022 review explicitly addresses this question and concludes that current evidence suggests topical rhEGF preparations do not stimulate cancer cell proliferation and do not initiate tumorigenesis. This is meaningful because it represents the current dermatology consensus, not just a manufacturer's claim.

The nuance gets lost when commercial competitors flatten "could accelerate growth of a pre-existing tumor in a specific clinical context" into "causes cancer." The first is a real, narrow contraindication you should respect. The second is a marketing distortion.

Claim 3: "Once EGF receptors are saturated, more EGF doesn't help."

This is true and is why we explicitly noted above that concentrations far above standard ranges do not produce proportionally larger effects. It is a reason not to overpay for ultra-high-concentration EGF serums. It is not a reason to avoid EGF entirely.

What this means in practice

Don't use EGF if any of the following apply to you:

Active or recent (within 2 years) skin cancer history in the treatment area
Active malignancy under treatment elsewhere
Active psoriasis flare on the treatment area (EGF can affect plaque keratinocyte proliferation)
Pregnancy or breastfeeding (insufficient safety data, default to caution)
Immunosuppressive medication regimens (consult your prescriber)
Isotretinoin use within the last 6 months (skin barrier is too compromised)

If none of those apply, and the contraindications listed in our pillar guide also do not apply, EGF is one of the best-evidenced, longest-studied, safest signaling molecules you can put into your skin.

Part 7: Realistic timeline and expectations

What actually happens with consistent EGF microinfusion, week by week.

Session 1, hours 1 to 24. Mild redness clears within 1 to 4 hours. Skin feels tight as the channels close, and slightly plumper than baseline. This is mostly hydration and barrier response, not yet EGF action.

Session 1, days 2 to 7. First post-session week. Skin feels smoother. Makeup applies more evenly. No structural change yet.

Session 2, week 2. Repeat of the first session's effects, with a slightly improved baseline. Some users notice an emerging "skin feels more responsive" quality, though this is hard to articulate and hard to photograph.

Weeks 3 to 4. Cumulative texture refinement starts to show in mirror inspection. Pore appearance improves marginally. Barrier function feels stronger (less reactive to weather, less dryness after cleansing).

Weeks 5 to 6, session 3. First "did you do something different?" moments from people who see you regularly. EGF's epidermal-thickening effect produces a subtle but real change in light reflection, which observers register as "you look fresh" or "your skin looks different."

Weeks 7 to 8, session 4. Inflection point. Fine line softening becomes visible in photos. Texture is smoother. Pigmentation, if you have post-inflammatory marks, has faded perceptibly. This is also where the EGF-specific effects (faster recovery from minor irritation, more resilient barrier) become clear in daily life rather than just on inspection.

Weeks 10 to 12, sessions 5 to 6. Compound effect is fully visible. Skin quality, not just appearance, has changed. Recovery from any sort of insult (a sunburn, a cold, a poorly-tolerated product) is faster than it was 12 weeks ago.

Months 4 to 6. Maintenance phase. Continuing every 14 days produces continuing improvement, though at a diminishing rate. By month six, results are less about visible change and more about durability of the new baseline.

If nothing has changed by week 8, the three most likely problems, in order:

Serum concentration is too low. Under 10 ppm rh-Oligopeptide-1 is unlikely to produce visible effect even with channel delivery.
Cadence has slipped below every 14 days. Skin needs the consistent stimulus to compound.
A competing skin issue is masking results. Untreated chronic inflammation, ongoing barrier damage, hormonal flares, or unmanaged skin conditions can absorb the gains EGF would otherwise produce. Treat the underlying issue first.

Frequently asked questions

Is EGF the same as growth factor? EGF is one of many growth factors. The term "growth factor" in skincare is a category, like "antioxidants" or "peptides." EGF (epidermal growth factor) is the most studied in dermatology. Other growth factors used in skincare include FGF (fibroblast growth factor), TGF-β (transforming growth factor beta), and IGF (insulin-like growth factor), each with somewhat different mechanisms.

Can I use EGF if I have melasma? With caution. EGF does not directly worsen melasma, but the mechanical microinfusion process can trigger inflammation that flares hormone-driven pigmentation. If your melasma is currently active, talk to a dermatologist before starting. Once melasma is stable, EGF microinfusion is generally well-tolerated with strict sun protection.

Does EGF expire? Yes. Recombinant EGF degrades over time, faster in heat and light. A single-use ampoule with a sealed expiration date is your best protection. A multi-use bottle of EGF serum past about 6 months from opening has likely lost a meaningful fraction of its activity, even with preservatives.

Can I just buy raw EGF concentrate and add it to my regular serum? You can, but the formulation outcome is unpredictable. The pH, preservative system, and other actives in your existing serum may degrade or destabilize the EGF. For microinfusion specifically, only use serums explicitly formulated for channel delivery, packaged in sterile ampoules.

How does barley-derived EGF compare to yeast-derived rh-EGF? Both produce molecularly identical recombinant human EGF. The manufacturing route differs, but the finished molecule is the same protein with the same biological activity. Brands that emphasize "barley EGF" are differentiating on production sustainability, not biological superiority.

Is EGF vegan? Recombinant EGF produced in barley or yeast is vegan, since no animal products are used in its production. Some older or premium products use EGF derived from animal cell culture; check the manufacturer's source if vegan status matters to you.

Should I refrigerate my EGF serum? Yes if the manufacturer recommends it (most do). If your serum is shelf-stable for unrefrigerated storage and the manufacturer says so explicitly, you do not have to refrigerate, but it does not hurt and it extends shelf life.

Can I use EGF on my hands and neck? Yes. The neck and chest age similarly to the face and respond to the same regenerative inputs. EGF microinfusion on the décolleté is increasingly common in clinic practice, and works well at home with the same cadence as the face.

What is the difference between EGF and stem cell extracts? Stem cell extracts contain a complex mixture of growth factors, signaling proteins, and cellular debris from cultured cells. EGF is one specific molecule. Stem cell extracts may contain EGF along with many other actives, or they may not. The labeling is often vague. If you specifically want EGF activity, look for rh-Oligopeptide-1, not "stem cell-derived" claims.

How long does an open ampoule stay good? Once opened and exposed to air, EGF degrades within hours. Use the entire ampoule in one session. Do not try to save half for next time.

Is microinfusion EGF FDA approved? EGF in skincare in the United States is regulated as a cosmetic ingredient, not a drug. Cosmetic ingredients do not require pre-market FDA approval. The FDA evaluates cosmetics for safety and labeling but does not pre-approve formulations. Some clinical-grade EGF products used in wound healing are approved as drugs in other countries, including South Korea and Cuba, where EGF has been used in burn and ulcer treatment for decades.

Does EGF help with hair growth on my scalp? The effect of EGF on human scalp hair is more complex than the wool-shedding sheep mechanism would suggest. Some studies suggest EGFR signaling supports normal hair cycle progression. Others suggest it can shorten the anagen phase. There is no current consensus, and EGF is not a recommended hair-loss treatment based on existing human evidence. If you are concerned about hair loss, the established evidence-based options are minoxidil, finasteride (for men), and microneedling at appropriate scalp depth.

The bottom line

EGF is one of the best-evidenced signaling molecules in skincare, with decades of clinical use in wound healing and a substantial body of dermatological research behind its cosmetic application. The case for adding it to your routine is strong if (1) you choose a serum with a real INCI listing at meaningful concentration, (2) you deliver it through micro-channels rather than relying on topical penetration alone, and (3) you understand the narrow contraindications around active skin cancer and psoriasis flares.

The case against EGF, made by a vocal contrarian camp, leans on a sheep-shearing technology and a category mistake (mitogenic versus mutagenic) that does not survive contact with the literature. Real contraindications exist. Sweeping safety panic is not one of them.

For at-home microinfusion users, EGF is a foundational ingredient. Rotate it with copper peptides and PDRN across your sessions. Hold the cadence at every 14 days. Protect your skin from the sun. Give the biology 8 to 12 weeks before evaluating. The results compound from there.

References (independently verified by the Skin Science Desk)

Shin SH, Koh YG, Lee WG, Seok J, Park KY. The use of epidermal growth factor in dermatological practice. International Wound Journal. 2022 Dec 30;20(6):2414-2423. doi: 10.1111/iwj.14075. PMID: 36584669. PMCID: PMC10333026. Verified 2026-04-30 against PMC full text.
Cohen S. Epidermal Growth Factor. Nobel Lecture, December 8, 1986. Nobel Foundation. Verified against Nobel Foundation archive.
Moore GP, Panaretto BA, Carter NB. Epidermal hyperplasia and wool follicle regression in sheep infused with epidermal growth factor. Journal of Investigative Dermatology. 1985;84(3):172-175. doi: 10.1111/1523-1747.ep12264699. PMID: 3871824. Verified 2026-04-30 against PubMed abstract.
CSIRO. Bioclip biological wool harvesting. Commercial release 1998. Verified against CSIRO archival records (CSIROpedia).
Schouest JM, Luu TK, Moy RL. Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum. Journal of Drugs in Dermatology. 2012;11(5):613-620. PMID: 22527430. Open-label, single-center, n=29; sponsored by ORF Genetics. Verified 2026-04-30 against PubMed abstract and JDD article.
Kang HC, Ahn SD, Choi DH, Kang MK, Chung WK, Wu HG. The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study. Radiation Oncology Journal. 2014;32(3):156-162. doi: 10.3857/roj.2014.32.3.156. PMID: 25324987. PMCID: PMC4194298. Verified 2026-04-30 against PMC full text.
Seidel R, Moy RL. Reduced appearance of under-eye bags with twice-daily application of epidermal growth factor (EGF) serum: a pilot study. Journal of Drugs in Dermatology. 2015 Apr;14(4):405-410. Verified against PubMed entry.

Additional studies cited in this article (Kim et al. 2014 split-face acne; the 36-patient acne scarring study; the EGFR-inhibitor pilot phase 3 trial) are referenced through the Shin et al. 2022 narrative review, where we have not independently retrieved the original primary papers. We have flagged these as review-cited rather than directly verified.

Editorial standards and corrections policy

This article was written by the EvenSkyn Skin Science Desk and reviewed against:

The Shin et al. 2022 narrative review in International Wound Journal (read in full)
Five primary peer-reviewed papers (read directly from PubMed and PMC abstracts/full texts)
Stanley Cohen's 1986 Nobel Lecture
CSIRO archival records on the Bioclip technology
Published commentary from the Pickart group on growth factor safety

Where we cite a clinical claim from a primary source, we have read the abstract or full text directly and the citation in the references section is marked "verified."

Where we cite a clinical claim that appears only in a peer-reviewed review without our independent confirmation of the primary paper, we attribute it to the reviewing author rather than the original trial authors. This is unusual transparency for consumer skincare content; it is intentional.

If you spot a factual error in this article, we want to know. Contact the Skin Science Desk via the email address in the EvenSkyn site footer. We correct errors publicly with a dated correction note at the bottom of the article. We answer substantive scientific questions within five business days.

Content is reviewed at least twice per year, or immediately when substantive new research warrants. Next scheduled review: October 30, 2026.

Conflict of interest disclosure

This content is intended for consumer education, not medical advice. If you have any active skin condition, are pregnant, are immunocompromised, are taking immunosuppressive medication, or have a personal or family history of skin cancer, consult a board-certified dermatologist before beginning any EGF-based at-home routine.

EvenSkyn manufactures at-home anti-aging skincare devices. We do not currently sell an EGF microinfusion kit. Our Under-Eye MicroInfuser patches use peptides, hyaluronic acid, niacinamide, caffeine, and Argireline rather than EGF, because the eye area benefits more from those specific actives than from growth factor signaling. We have no financial relationship with BIOEFFECT, ORF Genetics, Le Mieux, Glo Skin Beauty, Qure, ELIXA, or any other brand mentioned in this article. We name BIOEFFECT and ORF Genetics specifically because the most-cited cosmetic EGF trial (Schouest 2012) was funded by them, and disclosing that funding source is part of reading the evidence honestly.

EVENSKYN®

EGF in Skincare: How Epidermal Growth Factor Actually Works (and Why It Pairs So Well With Microinfusion)